William J Horne

US Patent:

6682739, Jan 27, 2004

Filed:

Jul 28, 2000

Appl. No.:

09/627775

Inventors:

Mark I. Greene - Penn Valley PA
Ramachandran Murali - Drexel Hill PA
Kazuhiro Aoki - Narashino, JP
William Carle Horne - Branford CT
Roland Baron - Guilford CT

Assignee:

The Trustees of the University of Pennsylvania - Philadelphia PA

International Classification:

A61K 3900

US Classification:

4241851, 424 851, 4241841, 4241921, 4241781, 514 12, 514 2, 514 8, 514885, 530350, 530351

Abstract:

Methods of inhibiting osteoclastogenesis and the activity of osteoclasts are disclosed. Methods of treating patients who have diseases characterized bone loss are disclosed. The present invention also provides peptides and peptide analogues designed from a binding loop of a member of the tumor necrosis factor receptor (TNF-R) superfamily. According to the methods, an amount of an inhibitor effective to inhibit osteoclastogenesis is administered to the patient. Methods of modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems in an individual are disclosed. The methods comprise the step of administering to the individual an amount of an inhibitor effective to modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems.

US Patent:

8642536, Feb 4, 2014

Filed:

Oct 14, 2009

Appl. No.:

12/578993

Inventors:

William S. Horne - Pittsburgh PA, US
Samuel H. Gellman - Madison WI, US
Lisa M. Johnson - Marshall MN, US

Assignee:

Wisconsin Alumni Research Foundation - Madison WI

International Classification:

A01N 37/18
A61K 38/55
A61P 31/18
C12N 5/071
A61K 38/00
C07K 5/00
C07K 7/00
C07K 16/00
C07K 17/00
A61K 38/04

US Classification:

514 41, 435366, 530324, 530325, 530326, 530333

Abstract:

Described is a method of fabricating biologically active, unnatural polypeptides. The method includes the steps of selecting a biologically active polypeptide or biologically active fragment thereof having an amino acid sequence comprising α-amino acid residues, and fabricating a synthetic polypeptide that has an amino acid sequence that corresponds to the sequence of the biologically active polypeptide, but wherein about 14% to about 50% of the α-amino acid residues found in the biologically active polypeptide or fragment of step (a) are replaced with β-amino acid residues, and the α-amino acid residues are distributed in a repeating pattern.